A large U.S. study found no evidence that taking Ozempic or Wegovy is tied to an increase in suicidal thoughts, researchers reported recently. 

研究人员最近报道说，一项大型美国研究没有发现证据表明服用Ozempic或Wegovy与自杀思想的增加有关。 

Both Ozempic for type 2 diabetes and the obesity treatment Wegovy have the same active ingredient, semaglutide. 

用于2型糖尿病的Ozempic和肥胖治疗Wegovy具有相同的活性成分，semaglutide。

The analysis included electronic medical record data from more than 1.8 million patients. Researchers actually found a lower risk of new and recurring suicidal thoughts in those taking semaglutide compared to those using other medications for weight loss or diabetes. 

该分析包括来自180万患者的电子病历数据。 研究人员实际上发现，与使用其他药物减肥或糖尿病的药物相比，在服用半卢替肽的人中，新的和反复出现的自杀思想的风险较低。 

Semaglutide belongs to a class of drugs known as GLP-1 agonists, which were designed to treat type 2 diabetes. In addition to helping control blood sugar levels, the drugs produce a feeling of fullness. 

半卢宾属于一类称为GLP-1激动剂的药物，这些药物旨在治疗2型糖尿病。 除了帮助控制血糖水平外，这些药物还会产生一种饱满感。 

Concerns over reports of suicidal ideation connected with semaglutide led to an investigation by the European Medicines Agency. The U.S. Food and Drug Administration (FDA) has listed suicidal ideation as a possible safety concern for GLP-1 drugs. 

人们对与Semaglutide有关的自杀念头的报道的担忧导致了欧洲药品局的调查。 美国食品药品监督管理局（FDA）已将自杀意念列为GLP-1药物的安全问题。 

A Reuters examination last year found that the FDA had received 265 reports of suicidal thoughts or behavior in patients taking semaglutide or similar medicines since 2010. Thirty-six of those reports describe a death by suicide or suspected suicide. 

路透检查员去年的一项检查发现，自2010年以来，FDA收到了265例服用Semaglutide或类似药物的患者的自杀念头或行为的报告。这些报告中有36例描述了自杀或怀疑自杀的死亡。 

Such events do not prove a connection between a drug and a side effect. But they can signal to officials a need to study a specific risk.

 此类事件不能证明药物与副作用之间的联系。 但是他们可以向官员发出信号，需要研究特定的风险。

The study appeared online in the journal Nature. It was funded by the U.S. National Institutes of Health. The researchers examined data on 240,258 U.S. patients prescribed Wegovy or other medications for weight loss and nearly 1.6 million with type 2 diabetes prescribed Ozempic or other treatments. 

该研究在《自然》杂志上在线出现。 它由美国国立卫生研究院资助。 研究人员检查了有关240,258名美国患者的数据，以减肥或其他药物为160万例服用Wegovy或其他药物，并使用了2型糖尿病开处方的Ozempic或其他治疗方法。